You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Neurofilament light chain serum levels reflect disease severity in MOG-Ab associated disorders

https://doi.org/10.1136/jnnp-2018-320287

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Presented at The data here reported have been presented at the ECTRIMS and EAN annual meeting, 2018.

    • Contributors SMA: sample collection, analysis and interpretation of MOG-Ab, AQP4-Ab and NfL results, design and conceptualisation of the study, data generation and interpretation, drafting the manuscript. SF: sample collection, interpretation of MOG-Ab, AQP4-Ab and NfL, design of the study. MG and DFR: interpretation of MOG and AQP4-Ab, collection and interpretation of clinical data. ES, RC, CRM, RO, RB, LZ, MZ, MDB, RT, FC, FR, AP, LG, GPS, LB, NM, FJ, VF, DFU, GS, LF, GC: collection and interpretation of clinical data. KS: analysis and interpretation of MOG-Ab and AQP4-Ab. DA: analysis and interpretation of MOG-Ab, AQP4-Ab, and NfL. MR: interpretation of MOG-Ab and AQP4-Ab, revising the manuscript for intellectual content. SMO: data interpretation and revising the manuscript for intellectual content. AG: statistical analysis, data generation, collection and interpretation of clinical data, design of the study.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sector.

    • Competing interests SMA was sponsored by Merck and Euroimmun for attending scientific meeting. SF was sponsored by Shire and Euroimmun for attending scientific meeting. RC received lecture fees and/or travel grants from Novartis, Biogen, Celgene, Novartis, TEVA, Genzyme and Sanofi-Aventis. MR was supported by a research grant from the Austrian Science Promotion Agency (FFG). The University Hospital and Medical University of Innsbruck (Austria; MR) receives payments for antibody assays (MOG, AQP4, and other autoantibodies) and for MOG and AQP4 antibody validation experiments organised by Euroimmun (Lübeck, Germany). SMO received honoraria from Biogen. AG received research support funding from Merck.

    • Patient consent for publication Not required.

    • Ethics approval The study protocol was approved by the Ethics Committee of Verona University Hospital (prog. 1052CESC Verona-Rovigo). All patients and controls consented to biological sample storage at the referring laboratory.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Data sharing statement The authors agree to share any unpublished data related to this study, which can be asked from the corresponding author.